Health-Care Investments

Strategic Capital in a Resilient, Innovation-Driven Sector: Healthcare is one of the most structurally resilient and economically essential sectors worldwide. Supported by demographic expansion, aging populations, rising healthcare expenditure, and continuous medical innovation, the sector offers a distinctive combination of defensive stability and long-term growth potential. Aveo Partners’ healthcare investment strategy is designed to capture sustainable value creation across pharmaceutical manufacturing, biotechnology, medical technology, and digital health infrastructure, segments that exhibit durable demand and relevance across economic cycles.

Capital allocation overview

Total capital allocated to healthcare: €3.5 billion

Healthcare represents a core strategic allocation within Aveo Partners’ broader diversified portfolio, accounting for approximately 15–20% of total managed capital. This weighting reflects the sector’s dual role as both a defensive anchor and a long-term structural growth engine. The allocation is structured across complementary healthcare sub-sectors to enhance diversification, reduce concentration risk, and balance income-generating exposures with innovation-led growth opportunities.

Capital Deployment Framework

Healthcare capital is deployed through a diversified strategy that balances stability with growth. A core allocation to established pharmaceutical, healthcare, and medical device companies provides recurring revenues, dividend income (where applicable), and long-term earnings growth, helping to anchor performance and support downside resilience. Selective exposure to biotechnology, advanced therapeutics, medical technology, and digital health adds innovation-led upside through product development milestones, regulatory approvals, strategic partnerships, and scalable SaaS or data-driven business models. Complementary investments in healthcare infrastructure and IT systems generate additional, contract-based and service-driven returns, creating a multi-layered return profile across the €3.5 billion healthcare allocation.

Capital Appreciation

Investments in companies that grow revenues, expand margins, successfully commercialize new products, and strengthen competitive positions can deliver long-term price appreciation.

Income Generation

Dividend-paying pharmaceutical, medical device, and select healthcare infrastructure companies contribute to a stable income component that supports overall portfolio yield.

Strategic Reinvestment

Profits realized from mature or fully valued positions are selectively reinvested into emerging healthcare innovations and undervalued opportunities, reinforcing the compounding effect over time.

Private Market Participation

Where strategies permit, selective investments in private healthcare businesses may generate enhanced return potential through value creation prior to public listing, strategic sale, or broader market recognition.

Active portfolio management

Healthcare investments are actively monitored to maintain alignment with strategic objectives, risk parameters, and evolving industry dynamics. Ongoing oversight includes analysis of revenue, earnings, and cash flow trends; assessment of R&D pipelines and product life cycles; monitoring of regulatory, pricing, and reimbursement developments; evaluation of competitive positioning and market share; and continuous review of valuations relative to fundamentals and peers. Allocations are adjusted when warranted to optimize exposure, preserve capital, and capture new opportunities.

Risk & Exposure Management Framework

Healthcare exposure is governed by a structured oversight model designed to enhance resilience while preserving growth participation. This framework applies clear position sizing discipline and concentration limits, diversifies across key healthcare sub-sectors—including pharmaceuticals, biotechnology, medical devices, digital health, and services—and maintains geographic diversification across major developed and select emerging markets, alongside ongoing regulatory and policy risk assessment.

Strategic Outcome

The healthcare investment strategy combines stability, innovation, and disciplined capital deployment to generate diversified return streams from the €3.5 billion allocation. Through structured sector allocation, active oversight, and alignment with global healthcare transformation, the portfolio is positioned to support long-term value creation while maintaining capital resilience.